Status:

COMPLETED

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

Lead Sponsor:

National Institute on Aging (NIA)

Conditions:

Acute ST Elevation Myocardial Infarction

Eligibility:

All Genders

21+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.

Detailed Description

REVEAL is a randomized, double-blinded, placebo-controlled, parallel phase II clinical study that will evaluate the effects of erythropoietin administration on infarct size, left ventricular remodelin...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Age greater than 21 years
  • Acute ST-elevation myocardial infarction
  • Referral for primary or rescue angioplasty
  • Revascularization procedure within 8 hours from the onset of ischemic symptoms
  • TIMI (Thrombolysis in myocardial infarction) flow grade 0 or 1 in the culprit coronary artery at the beginning of coronary angiography
  • Successful revascularization of infarct-related artery
  • EXCLUSION CRITERIA:
  • Clinical indication for erythropoietin
  • STEMI (ST-elevation myocardial infarction) due to occlusion of a branch vessel
  • Any history of prior MI, PCI (Percutaneous coronary intervention), CABG (Coronary artery bypass graft), cardiomyopathy, myocarditis, or CHF (congestive heart failure)
  • Hypersensitivity to human albumin, mammalian cell-derived products, or erythropoietin
  • Hematocrit greater than 42% in men or greater than 40% in women at the time of study drug administration
  • Uncontrolled hypertension at the time of study drug administration
  • Cardiogenic shock
  • Need for coronary surgical revascularization as determined at the time of the index coronary catheterization
  • History of hypercoagulable disorder, thromboembolic event, or venous thrombosis
  • History of stroke or TIA (transient ischemic attack)
  • History of seizures
  • Contraindication to MRI
  • Pregnancy or nursing mother

Exclusion

    Key Trial Info

    Start Date :

    September 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2011

    Estimated Enrollment :

    223 Patients enrolled

    Trial Details

    Trial ID

    NCT00378352

    Start Date

    September 1 2005

    End Date

    January 1 2011

    Last Update

    May 9 2017

    Active Locations (16)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (16 locations)

    1

    Washington Hospital Center

    Washington D.C., District of Columbia, United States, 20010

    2

    University of Miami, School of Medicine

    Miami, Florida, United States, 33136

    3

    Emory University Hospital

    Atlanta, Georgia, United States, 30322

    4

    Henry Ford Hospital

    Detroit, Michigan, United States, 48202